Zhejiang CONBA Pharmaceutical Co.,Ltd. (SHA:600572)
China · Delayed Price · Currency is CNY 4.520
+0.010 (0.22%)
Aug 29, 2025, 2:45 PM CST
SHA:600572 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
Net Income | 595.75 | 622.42 | 591.57 | 358.12 | 2,017 | 453.3 | Upgrade |
Depreciation & Amortization | 337.8 | 337.8 | 324.35 | 277.48 | 286.68 | 266.07 | Upgrade |
Other Amortization | 16.19 | 16.19 | 8.77 | 9.38 | 17.41 | 12.7 | Upgrade |
Loss (Gain) From Sale of Assets | -20.55 | -20.55 | -35.68 | -36.51 | -43.18 | 1.31 | Upgrade |
Asset Writedown & Restructuring Costs | 5.46 | 5.46 | 7.18 | 2.33 | 96.67 | 104.69 | Upgrade |
Loss (Gain) From Sale of Investments | -96.87 | -96.87 | 61.31 | 202.15 | -1,881 | -318.2 | Upgrade |
Provision & Write-off of Bad Debts | 1.63 | 1.63 | 1.07 | 0.24 | 36.57 | 12.12 | Upgrade |
Other Operating Activities | 115.31 | 99.27 | 155.42 | 163.86 | 269.06 | 271.16 | Upgrade |
Change in Accounts Receivable | 138 | 138 | -271.44 | 47.95 | -360.47 | 177.01 | Upgrade |
Change in Inventory | 19.2 | 19.2 | -244.97 | -111.02 | -158.76 | 239.36 | Upgrade |
Change in Accounts Payable | -145.41 | -145.41 | 358.69 | 246.19 | 341.51 | -60.54 | Upgrade |
Change in Other Net Operating Assets | 24 | 24 | 26.36 | 4.79 | 30.52 | 24.71 | Upgrade |
Operating Cash Flow | 1,002 | 1,013 | 898.64 | 1,155 | 891.23 | 1,250 | Upgrade |
Operating Cash Flow Growth | 2.54% | 12.67% | -22.23% | 29.65% | -28.68% | 35.03% | Upgrade |
Capital Expenditures | -252.26 | -290.63 | -209.14 | -291.75 | -581.42 | -460.4 | Upgrade |
Sale of Property, Plant & Equipment | 23.84 | 23.83 | 96.34 | 164.01 | 21.02 | 13.5 | Upgrade |
Cash Acquisitions | - | - | 8.79 | -206.31 | - | - | Upgrade |
Divestitures | - | - | - | -0.01 | 1,479 | -0.23 | Upgrade |
Investment in Securities | -505.62 | 22.74 | -207.13 | 94.24 | 168.48 | 275.65 | Upgrade |
Other Investing Activities | 34.96 | 32.56 | 22.09 | 28.72 | 0.31 | 4.7 | Upgrade |
Investing Cash Flow | -699.08 | -211.5 | -289.05 | -211.11 | 1,087 | -166.77 | Upgrade |
Long-Term Debt Issued | - | 750.27 | 1,755 | 1,760 | 1,912 | 2,892 | Upgrade |
Total Debt Issued | 395.11 | 750.27 | 1,755 | 1,760 | 1,912 | 2,892 | Upgrade |
Long-Term Debt Repaid | - | -1,565 | -1,716 | -2,060 | -2,791 | -3,716 | Upgrade |
Net Debt Issued (Repaid) | -815.48 | -815.11 | 38.44 | -300.45 | -879.27 | -823.4 | Upgrade |
Issuance of Common Stock | 54.24 | 48.7 | - | 1.5 | - | - | Upgrade |
Repurchase of Common Stock | -299.99 | -299.99 | - | - | - | - | Upgrade |
Common Dividends Paid | -517.9 | -523.54 | -420.13 | -490.35 | -85.01 | -142.8 | Upgrade |
Other Financing Activities | -211.14 | -324.96 | -337.4 | -135.41 | -61.74 | -61.56 | Upgrade |
Financing Cash Flow | -1,790 | -1,915 | -719.08 | -924.71 | -1,026 | -1,028 | Upgrade |
Foreign Exchange Rate Adjustments | 6.09 | 5.11 | 2.99 | 9.11 | 0.05 | -6.25 | Upgrade |
Net Cash Flow | -1,481 | -1,109 | -106.51 | 28.77 | 952.21 | 48.92 | Upgrade |
Free Cash Flow | 749.64 | 721.9 | 689.5 | 863.73 | 309.8 | 789.3 | Upgrade |
Free Cash Flow Growth | 0.00% | 4.70% | -20.17% | 178.80% | -60.75% | 20.19% | Upgrade |
Free Cash Flow Margin | 11.76% | 11.08% | 10.24% | 14.39% | 4.72% | 13.36% | Upgrade |
Free Cash Flow Per Share | 0.28 | 0.28 | 0.27 | 0.34 | 0.12 | 0.31 | Upgrade |
Cash Income Tax Paid | 520.46 | 518.05 | 722.62 | 562.67 | 619.14 | 659.23 | Upgrade |
Levered Free Cash Flow | 66.13 | 518.17 | 664.78 | 602.51 | -18.09 | 549.03 | Upgrade |
Unlevered Free Cash Flow | 75.46 | 531.16 | 687.53 | 633.43 | 27.67 | 626.31 | Upgrade |
Change in Working Capital | 47.18 | 47.18 | -215.36 | 178.43 | 91.26 | 446.55 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.